Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals
Evonik Hones Pharma Focus with Sale of U.K. Unit
12:54 PM MST | December 12, 2008 | Alex Scott
Evonik says the recent sale of its Seal Sands, U.K. fine chemical facility and the planned introduction in the next few weeks of a pharmaceutical ingredient facility at Nanning, China will “significantly” increase its active pharma ingredient (API) production capacity while reducing its exposure to potentially lower-value non-GMP material production. Also, the Seal Sands divestment was made without the Evonik group losing any chemistries, Rudolf Hanko, head of Evonik’s Exclusive Synthesis & Amino Acids business line, tells CW. Evonik...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee